Kazia Therapeutics Limited (KZIA)
Develops experimental cancer drugs that cross the blood-brain barrier to treat brain tumors
$12.69+0.04%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+55.1%
The outlook
Analysts are strongly bullish on KZIA, with an average rating of 1.4 out of 5 and a target price roughly double the current level. The stock sits in the middle of its 52-week range with mixed momentum against recent moving averages. The overall lean is decidedly positive based on analyst conviction.
What’s behind the score
Analyst consensusStrong Buy — 1.4 avg of 5 analysts
Price trendMixed vs its moving averages
52-week range62% of the way from its 52-week low to high
Price targetAvg target +118% vs current price
Analyst price target
~12-month · 5 analysts$27.63average target+117.8% vs now
Now $12.69
Low $17.49High $33.98
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$145.0M
52-wk high
$17.40
52-wk low
$4.86
50-day avg
$13.10
200-day avg
$9.65
Trailing P/E
—